DR. KEVIN J VASKA, MD
Osteopathic Medicine at Minnesota Ave, Sioux Falls, SD
License number
South Dakota 1537
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
South Dakota 27508-020
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
South Dakota 29328
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
6709 S Minnesota Ave STE 101, Sioux Falls, SD 57108
Phone
(605) 274-6300
(605) 333-4875 (Fax)
(605) 333-4875 (Fax)
Personal information
See more information about KEVIN J VASKA at radaris.comName
Address
Phone
3562 S Spencer Blvd, Sioux Falls, SD 57103
3562 Spencer Blvd, Sioux Falls, SD 57103
1310 22Nd St, Sioux Falls, SD 57105
1310 22Nd St, Sioux Falls, SD 57105
2409 Marson Dr, Sioux Falls, SD 57103
Professional information
Dr. Kevin J Vaska, Sioux Falls SD - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
Sioux Falls Cardiovascular
6709 S Minnesota Ave, Sioux Falls 57108
(605) 274-6300 (Phone)
6709 S Minnesota Ave, Sioux Falls 57108
(605) 274-6300 (Phone)
Procedures:
Ablation for Treatment of Cardiac Arrythmias, Cardiac Catheterization (incl. Coronary Angiography), Cardiac Imaging, Cardiac Myocardial Perfusion Imaging, Cardioversion, Elective, Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair, Chest CT (incl. Heart and Lungs), Coronary Angioplasty, Atherectomy and Stent, Peripheral Artery Catheterization, Thrombolysis, Tilt Testing or Cardiac Event Monitors
Conditions:
Aneurysm and Dissection of Heart, Angina and Acute Coronary Syndrome, Aortic Aneurysm, Aortic Dissection, Aortic Valve Disease, Arrhythmias (incl. Atrial Fibrillation), Autonomic Disorders, Cardiomegaly, Cardiomyopathy, Carotid Artery Disease, Congenital Heart Disease, Congestive Heart Failure, Coronary Artery Disease (CAD), Endocarditis, Heart Attack (Acute Myocardial Infarction), Hyperlipidemia, Hypertension, Hypertensive Heart and Chronic Kidney Disease, Hypertensive Heart Disease, Hypotension, Mitral Valve Disease, Pericardial Disease, Pulmonary Hypertension, Pulmonary Valve Disease, Septal Defect, Syncope, Tricuspid Valve Disease
Certifications:
Cardiovascular Disease, 1989, Internal Medicine, 1985
Languages:
English
Education:
Medical School
Sanford School Of Medicine Of The University Of South Dakota
Graduated: 1982
Royal C Johnson Va Hospital
Graduated: 1983
University Sd
Graduated: 1986
Med College Of Wisconsin
Graduated: 1989
Sanford School Of Medicine Of The University Of South Dakota
Graduated: 1982
Royal C Johnson Va Hospital
Graduated: 1983
University Sd
Graduated: 1986
Med College Of Wisconsin
Graduated: 1989
Background:
Sanction: 1 time(s)
Board Action: 1 time(s)
Board Action: 1 time(s)
Kevin James Vaska, Sioux Falls SD
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Sioux Falls Cardiovascular
6709 S Minnesota Ave, Sioux Falls, SD 57108 Sioux Falls Cardiovascular
1727 S Cleveland Ave, Sioux Falls, SD 57103 Avera Mckennan Hospital & University Health Center
1325 S Cliff Ave, Sioux Falls, SD 57105 Avera Heart Hospital of South Dakota Llc
4500 W 69Th St, Sioux Falls, SD 57108
6709 S Minnesota Ave, Sioux Falls, SD 57108 Sioux Falls Cardiovascular
1727 S Cleveland Ave, Sioux Falls, SD 57103 Avera Mckennan Hospital & University Health Center
1325 S Cliff Ave, Sioux Falls, SD 57105 Avera Heart Hospital of South Dakota Llc
4500 W 69Th St, Sioux Falls, SD 57108
Education:
University of South Dakota(1982)
Bonding Tissues And Cross-Linking Proteins With Naphthalimide Compounds
US Patent:
2005011, May 26, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982197
Inventors:
Ronald Utecht - Volga SD, US
Kaia Kloster - Hudson SD, US
Millard Judy - Redmond WA, US
Kevin Vaska - Sioux Falls SD, US
James Matthews - Dallas TX, US
Kaia Kloster - Hudson SD, US
Millard Judy - Redmond WA, US
Kevin Vaska - Sioux Falls SD, US
James Matthews - Dallas TX, US
Assignee:
PhotoBioMed Corporation - Dallas TX
International Classification:
A61K038/17, C07K014/47, C08B037/08
US Classification:
514002000, 530409000, 536018700, 514055000, 536020000
Abstract:
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
Bonding Tissues And Cross-Linking Proteins With Naphthalimide Compounds
US Patent:
8632565, Jan 21, 2014
Filed:
Feb 21, 2013
Appl. No.:
13/772543
Inventors:
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Assignee:
Alumend, LLC - Sioux Falls SD
International Classification:
A61B 17/08, A61D 1/00, A61K 38/00, A01N 43/04
US Classification:
606214, 514 11, 514 55
Abstract:
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
Bonding Tissues And Cross-Linking Proteins With Naphthalimide Compounds
US Patent:
8546384, Oct 1, 2013
Filed:
Jul 12, 2012
Appl. No.:
13/547196
Inventors:
Ronald E. Utecht - Volga SD, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Assignee:
Alumend, LLC - Sioux Falls SD
International Classification:
A61K 31/535
US Classification:
5142295
Abstract:
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
Bonding Tissues And Cross-Linking Proteins With Naphthalimide Compounds
US Patent:
8242114, Aug 14, 2012
Filed:
Mar 19, 2009
Appl. No.:
12/407481
Inventors:
Ronald E. Utecht - Volga SD, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Assignee:
Alumend LLC - Sioux Falls SD
International Classification:
A61K 31/55
US Classification:
5142295
Abstract:
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
Bonding Tissues And Cross-Linking Proteins With Naphthalimide Compounds
US Patent:
2013023, Sep 5, 2013
Filed:
Feb 21, 2013
Appl. No.:
13/772510
Inventors:
Ronald E. Utecht - Volga SD, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Kaia L. Kloster - Hudson SD, US
Millard M. Judy - Redmond WA, US
Kevin J. Vaska - Sioux Falls SD, US
James L. Matthews - Dallas TX, US
Assignee:
Alumend, LLC - Sioux Falls SD
International Classification:
A61K 41/00, A61K 8/73, A61Q 17/04, A61K 31/722
US Classification:
424 59, 514 55
Abstract:
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.